At the news
? NEUTRALIMPACT 2/10 CLUSTER filed Nov 6, 2026 at 16:03 ET
Two Teva insiders, including a senior executive (Sabag Mark, See Remarks), sold shares in open-market transactions totaling $2.29M in the days following the company's Q3 2026 earnings beat and raised guidance. The sales are not under 10b5-1 plans and represent 0.005% of market cap, a trivial amount relative to the $48.8B valuation.
- Two insiders executed open-market sales (code S) totaling $2.29M, none under 10b5-1 plans
- Sabag Mark sold 46,000 shares at $41.93 for $1.93M on 2026-11-05
- Bergwerk Dov sold 17,505 shares at $41.72 for $730K and 8,755 shares at $41.72 for $365K on 2026-11-04
- Sales occurred 1-2 days after Teva reported Q3 2026 non-GAAP EPS of $0.86 (beat consensus by 19.4%) and revenue of $4.395B (above $4.23B consensus)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access